We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to ...

Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab ...

In trading on Tuesday, shares of Immunovant Inc (Symbol: IMVT) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15 per share. By comparison ...

BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data ...

KLP Kapitalforvaltning AS purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 10,800 shares of ...

The last time I wrote an article on Immunovant, Inc. (NASDAQ:IMVT), it was in a Seeking Alpha article entitled "Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study." In that article ...

Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical ...